AbbVie Reports $216M Acquired IPR&D Expense and Updates 2026 EPS Guidance

Summary of Filing

On October 5, 2026, AbbVie Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to provide an update regarding third-quarter 2026 acquired in-process research and development (IPR&D) and milestones expense, along with updated adjusted diluted earnings per share (EPS) guidance.

Key Disclosures

1. Q3 2026 Acquired IPR&D & Milestones Impact:

   • Pre-tax acquired IPR&D and milestones expense is estimated at $216 million for the quarter ended September 30, 2026.
   • Unfavorable impact of $0.11 per share on both GAAP diluted EPS and adjusted non-GAAP diluted EPS.

2. Guidance Adjustments:

   • Third-Quarter 2026 Adjusted Diluted EPS: Updated to $3.73 – $3.77 (compared to the previous guidance range of $3.84 – $3.88, reflecting the exact $0.11 impact).
   • Full-Year 2026 Adjusted Diluted EPS: Updated to $13.76 – $13.96 (compared to the previous guidance range of $13.87 – $14.07 announced on July 31, 2026).
   • AbbVie notes that full-year guidance excludes potential acquired IPR&D and milestones expense beyond Q3 2026 due to inherent timing uncertainty.

Market & Trading Significance

• Impact Rating: Medium. Pharmaceutical companies often furnish these pre-earnings updates to align Wall Street consensus models with quarter-to-date milestone and collaboration payments. Because the $0.11 reduction corresponds directly to the $216 million accounting impact rather than operational underperformance, the operational baseline remains consistent with prior management expectations.